ID-MAGIC: Individualised Dose optiMisAtion of Ganciclovir in Immunocompromised Children Trial

This is a multicentre, pragmatic, adaptive, two-arm, open label randomised control trial at seven major paediatric hospitals in Australia and New Zealand aims to determine in immunocompromised children with cytomegalovirus viraemia whether individualised intravenous ganciclovir dosing using a web app is superior to standard intravenous ganciclovir dosing in achieving virological clearance.